ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2093

Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort

Farah Tamirou and Frédéric A. Houssiau, Cliniques Universitaires Saint-Luc, Brussels, Belgium

Meeting: ACR Convergence 2022

Keywords: Lupus nephritis, Outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: While long-term follow-up (FU) is needed to unmask poor outcome in lupus nephritis (LN), most clinical trials evaluate outcome measures at short-term. Early endpoints predictive of long-term outcome in LN are therefore most welcome to compare efficacy of pharmacological interventions. A multicentric study, using a large database of prospectively followed LN patients, succeeded in computing equations (hazard index; HI) predicting adverse kidney outcomes, i.e. chronic kidney disease (CKD), severe kidney injury (SKI) and renal replacement therapy (RRT). These HI were calculated with data measured within the first year of treatment. The HI values were significantly higher in patients experiencing long-term poor renal outcomes after 4 years of follow-up (FU) (Mackay M et al. Arthritis Rheumatol 2016; 68 (suppl.10), abstract 967). We confirmed the validity of the HI equations in an independent cohort (Tamirou F et al. Arthritis Rheumatol 2018; 70 (suppl.10), abstract 1945). The initial HI equations were revised in a subsequent analysis (Mackay M et al. Arthritis Rheumatol 2019;71;411-419), taking into account additional baseline data.

To validate the revised HI for CKD, SKI and RRT in the Louvain LN cohort followed for ≥ 4 years and to check their validity to predict RTT in patients followed for a longer period.

Methods: Data from 262 consecutive LN patients followed in our lupus center were screened. Only those for whom clinical data were available following their first episode of proliferative and/or membranous biopsy-confirmed LN were selected. Serum creatinine and proteinuria at different time points from 131 LN patients followed for ≥ 4 years were analyzed. At last FU, patients were divided according to the presence or absence of CKD, SKI and RRT. Their respective HI, measured at one year, were compared. CKD/SKI were defined as ≥ 30%/≥ 50% decrease in eGFR (CKD-EPI equation), compared to the highest value measured within the first year.

Results: As illustrated in the Table, the mean HI for CKD and SKI, measured at one year, were significantly higher in the groups of patients who indeed developed CKD and SKI after a FU of ≥ 4 years compared to those who did not. The mean HI for RRT was higher in patients who developed RRT after ≥ 4 years but the difference was not statistically significant (p=0.07), most likely due to the small numbers of RRT in this series at this time-point (n=5). After a longer FU (mean ± SD: 15 ± 7 years), more RRT were observed (n=10) and the mean HI for RRT became significantly higher in patients suffering from RRT compared to those who did not. Of note, clinical (gender, age, mean serum creatinine, mean serum creatinine, mean proteinuria) and pathological (ISN/RPS class) characteristics did not differ at baseline between patients with poor long-term renal outcome compared to the others.

Conclusion: We confirm the validity of the revised HI equations as early predictors of poor renal outcomes in a cohort of incident LN, including for RRT. These HI tools could be proposed as outcome measures in LN clinical trials.

Supporting image 1


Disclosures: F. Tamirou, None; F. Houssiau, None.

To cite this abstract in AMA style:

Tamirou F, Houssiau F. Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/hazard-index-equations-using-data-collected-at-baseline-and-after-one-year-treatment-allow-early-prediction-of-poor-outcome-in-an-incident-lupus-nephritis-population-data-from-the-louvain-lupus-nephr/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hazard-index-equations-using-data-collected-at-baseline-and-after-one-year-treatment-allow-early-prediction-of-poor-outcome-in-an-incident-lupus-nephritis-population-data-from-the-louvain-lupus-nephr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology